ORCID Profile
0000-0003-0359-5970
Current Organisation
Uppsala University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Chemical Society (ACS)
Date: 18-02-2020
Publisher: MDPI AG
Date: 20-02-2017
Publisher: American Chemical Society (ACS)
Date: 07-02-2023
Publisher: Wiley
Date: 16-05-2018
DOI: 10.1002/MRC.4737
Publisher: American Chemical Society (ACS)
Date: 08-09-2022
Publisher: Royal Society of Chemistry (RSC)
Date: 2022
DOI: 10.1039/D2CC00994C
Abstract: The interaction of a [bis(pyridine)iodine( i )] + cation with a [bis(pyridine)silver( i )] + cation, in which an iodonium ion acts as a nucleophile by transferring electron density to the silver( i ) cation, is reinvestigated herein.
Publisher: American Chemical Society (ACS)
Date: 13-08-2020
Publisher: American Chemical Society (ACS)
Date: 27-08-2020
Publisher: MDPI AG
Date: 29-07-2019
DOI: 10.3390/MOLECULES24152746
Abstract: Phytochemical investigations of ethanol root bark and stem bark extracts of Cleistochlamys kirkii (Benth.) Oliv. (Annonaceae) yielded a new benzopyranyl cadinane-type sesquiterpene (cleistonol, 1) alongside 12 known compounds (2–13). The structures of the isolated compounds were established from NMR spectroscopic and mass spectrometric analyses. Structures of compounds 5 and 10 were further confirmed by single crystal X-ray crystallographic analyses, which also established their absolute stereochemical configuration. The ethanolic crude extract of C. kirkii root bark gave 72% inhibition against the chloroquine-sensitive 3D7-strain malaria parasite Plasmodium falciparum at 0.01 μg/mL. The isolated metabolites dichamanetin, (E)-acetylmelodorinol, and cleistenolide showed IC50 = 9.3, 7.6 and 15.2 μM, respectively, against P. falciparum 3D7. Both the crude extract and the isolated compounds exhibited cytotoxicity against the triple-negative, aggressive breast cancer cell line, MDA-MB-231, with IC50 = 42.0 μg/mL (crude extract) and 9.6–30.7 μM (isolated compounds). Our findings demonstrate the potential applicability of C. kirkii as a source of antimalarial and anticancer agents.
Location: United States of America
No related grants have been discovered for Mate Erdelyi.